AstraZeneca’s Brilinta shows benefits for heart attack patients in new study

AstraZeneca has announced the findings of a new clinical trial showing the effectiveness of Brilinta in the treatment of heart attack survivors with multi-vessel disease.

A new sub-analysis of the phase III PEGASUS-TIMI 54 trial demonstrated a risk reduction of 19 percent in cardiovascular death, myocardial infarction or stroke and of 36 percent in coronary death following treatment with Brilinta in combination with low-dose aspirin.

This builds on previous analysis that has demonstrated the five-year ischaemic risk reduction benefits Brilinta can provide post-heart attack, as well as the long-term cardiovascular protection it offers.

Brilinta works by inhibiting platelet activation and has been shown to reduce the rate of atherothrombotic cardiovascular events, such as heart attack or cardiovascular death, in patients with acute coronary syndromes.

Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases for AstraZeneca's global medicines development unit, said: "These results show that for patients with multi-vessel disease who have survived a heart attack and remain at risk of suffering a potentially deadly follow-on event, the extended use of Brilinta offers added protection."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.